# E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma

> **NCT01271504** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 102 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sorafenib
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT01271504
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-19
- **Primary completion:** 2015-06-23
- **Final completion:** 2015-06-23
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2021-05-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01271504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01271504, "E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01271504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*